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Serum level of adiponectin is a surrogate
independent biomarker of radiographic disease
progression in early rheumatoid arthritis: results
from the ESPOIR cohort
Magali Meyer1,2,3†, Jérémie Sellam1,2,3†, Soraya Fellahi2,3,4, Salma Kotti5, Jean-Philippe Bastard2,3,4, Olivier Meyer6,
Frédéric Lioté7, Tabassome Simon2,5, Jacqueline Capeau2,3,4 and Francis Berenbaum1,2,3*
Abstract
Introduction: Adipokines such as adiponectin, leptin, and visfatin/nicotinamide phosphoribosyltransferase (NAMPT)
have recently emerged as pro-inflammatory mediators involved in the pathophysiology of rheumatoid arthritis (RA).
We aimed to determine whether serum adipokine levels independently predicted early radiographic disease
progression in early RA.
Methods: In total, 791 patients were included from the prospective Etude et Suivi des POlyarthrites Indifférenciées
Récentes (ESPOIR) cohort who met the American College of Rheumatology-European League Against Rheumatism
criteria for RA (n = 632) or had undifferentiated arthritis (UA) (n = 159). Enzyme-linked immunosorbent assay (ELISA) was
used to assess baseline serum levels of adiponectin, leptin, and visfatin/NAMPT. In the RA group, we tested the
association of serum adipokine levels and (a) baseline radiographic damage and (b) radiographic disease progression,
defined as a change >0 or ≥5 in total Sharp-van der Heijde Score (∆SHS) between inclusion and 1 year (∆SHS ≥1 or
rapid radiographic progression: ∆SHS ≥5), adjusting for confounders (age, sex, body-mass index, insulin resistance,
C-reactive protein level, Disease Activity Score in 28 joints, Health Assessment Questionnaire score, autoantibody status,
steroid use, and radiographic evidence of RA damage at inclusion).
Results: Adiponectin level was independently associated with baseline total SHS (adjusted β = 0.12; P = 0.006). It was
also associated with ∆SHS ≥1 (adjusted odds ratio (aOR) = 1.84 (1.25 to 2.72)) involving erosive as well as narrowing
disease progression (aOR = 1.73 (1.17 to 2.55) and 1.93 (1.04 to 3.57), respectively). Serum adiponectin level predicted
∆SHS ≥5 (aOR = 2.0 (1.14 to 3.52)). Serum leptin level was independently associated only with ∆SHS >0 (aOR = 1.59
(1.05 to 2.42)). Conversely, serum visfatin/NAMPT level and radiographic disease progression were unrelated.
Considering the receiver-operated characteristic curves, the best adiponectin cut-offs were 4.14 μg/ml for ∆SHS ≥1 and
6.04 μg/ml for ∆SHS ≥5, with a good specificity (58% and 75% for ∆SHS ≥1 and ∆SHS ≥5, respectively) and high
negative predictive values (75% and 92% for ∆SHS ≥1 or ∆SHS ≥5, respectively).
Conclusion: Serum adiponectin level is a simple useful biomarker associated with early radiographic disease
progression in early RA, independent of RA-confounding factors and metabolic status.
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Introduction
In rheumatoid arthritis (RA), early diagnosis and early
therapeutic intervention improve clinical outcomes and
reduce the accrual of joint damage and major irreversible
long-term disability. Patients with early RA should be
actively treated as soon as the disease is diagnosed [1].
Finding serum biomarkers that can be used to identify
patients at high risk of structural disease progression early
in the disease is important because joint lesions occur
mainly during this period and may be reduced by early
treatment [2]. Levels of inflammatory biomarkers (that is,
C-reactive protein (CRP) and erythrocyte sedimentation
rate (ESR)) and presence of autoantibodies (that is, rheu-
matoid factor (RF) and anti-cyclic citrullinated peptide
[anti-CCP] antibodies) are associated with subsequent RA
structural severity [3-5]. However, the predictive value of
these markers for early radiographic disease progression
remains weak, especially in early disease, which supports
the need for more sensitive and specific biomarkers [6].
Adipokines are adipose tissue-specific soluble proteins
also produced by synovium and cartilage, as well as
mononuclear blood cells; they are quantifiable in bio-
logic fluids [7]. The most studied are adiponectin, leptin,
and visfatin (also known as nicotinamide phosphoribo-
syltransferase (NAMPT)). These soluble mediators have
pleiotropic effects and participate in several metabolic,
immune, and inflammatory processes [7-9]. Adiponectin
is the most abundant adipokine detected in the serum
and has unique properties by acting as an antidiabetic
and antiatherogenic mediator [10,11]. However, despite
the cardioprotective properties of adiponectin and con-
sidering the complexity of its effects, a high serum level
of adiponectin was found to be associated with mortality
in kidney diseases and type 1 diabetes; this increased
level is paradoxically considered as a beneficial physio-
logical response [10-14]. In type 1 diabetes, increased
leptin levels are positively associated with β-cell function
[15]. In nonrheumatic conditions, serum ratio of adipo-
nectin to leptin may be a noninvasive marker of the
severity of nonalcoholic fatty liver disease [16].
The important role of adipokines in inflammation pro-
vides novel links between adipose tissue, adipokines, and
inflammation-related disorders, including RA [11]. There-
fore, adipokines could represent potential disease bio-
markers and therapeutic targets in clinical practice. Recent
findings have demonstrated that these mediators have po-
tent actions on tissue and cells involved in RA, including
cartilage, synovium, bone, and various immune cells [17].
Adipokines as serum biomarkers reflecting RA-related
radiographic damage were recently reported in two cross-
sectional studies of 167 and 197 subjects [18,19]. Moreover,
serum adiponectin level as a predictor of radiographic
disease progression has been suggested in two longitudinal
studies of 152 patients with established RA and 253 with
early RA [20,21]. However, in all these studies, several im-
portant confounding factors, such as metabolic disorders,
especially insulin resistance, were not taken into account.
Further to assess the role of adipokines as serum bio-
markers for early radiographic disease progression in
RA, we determined in a large cohort of patients with
early arthritis whether serum adipokine levels (a) were
increased in early RA as compared with undifferentiated
arthritis (UA), and (b) could predict radiographic struc-
tural progression in patients with early RA, and espe-
cially rapid radiographic progression.
Methods
Patients
The population and methods of the ESPOIR cohort
(Etude et Suivi des POlyarthrites Indifférenciées Récentes)
were described in detail elsewhere [22]. Diagnosis of
RA was defined as fulfilling the American College of
Rheumatology-European League Against Rheumatism
(ACR-EULAR) 2010 criteria for RA at inclusion [1].
Otherwise and with no other defined diagnosis at inclu-
sion, patients were considered to have UA. Patients with
other defined diagnoses were not assessed for serum adi-
pokine level. The Montpellier (France) Ethics Committee
approved the study in July 2002, and all patients provided
informed consent.
Serum assays
At inclusion, blood samples were taken for investigation
of glycemia, C-reactive protein (CRP) level, and ery-
throcyte sedimentation rate (ESR). Serum samples were
collected at enrolment and immediately stored at −80°C
in a single biologic resource centre. A central laboratory
was used for determining anti-citrullinated cyclic peptide
(anti-CCP) antibodies (anti-CCP2; Dia-Sorin, Saluggia
(Vercelli), Italy; positive >50 U/ml) and rheumatoid fac-
tor (RF) (Menarini France, Rungis Cedex, France; po-
sitive >9 IU/ml) with enzyme-linked immunosorbent
assay (ELISA), as previously described [23]. ELISA kits
were used for assay of serum levels of total adiponectin
(Bühlman, Basel, Switzerland), leptin (Quantikine; R&D
Systems, Oxford, UK), and visfatin/NAMPT (Bühlman,
Basel, Switzerland). Insulinemia, used for calculation of
the Homeostatic Model Assessment of Insulin Resistance
(HOMA-IR) index, was assayed with chemiluminescence
(ARCHITECT Insulin, Abbott Park, IL, USA).
Radiologic data
Radiographs of the hands and wrists (anteroposterior
view) and the feet (anteroposterior and oblique views)
were available at inclusion and at 1 year. The interpre-
tation was standardized, as described previously [22,24].
Radiographs were read by the patient’s office-based
rheumatologist to determine the presence or absence of
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abnormalities related to RA. Then, for quantitative
scoring, radiographs were sent to the coordinating cen-
ter for calculation of the total, joint erosion, and nar-
rowing Sharp/van der Heijde score (SHS) at inclusion
and 1 year by two experienced readers with blinding to
patient data. Missing data were excluded from the
analysis.
Statistical analysis
Continuous variables are described as mean ± standard
deviation (SD), and categoric variables as frequencies
and percentages. The distributions of all variables were
examined. Serum levels of adiponectin, leptin, visfatin/
NAMPT, and CRP, Health Assessment Questionnaire
(HAQ) score, and SHS values were not normally distri-
buted and thus were log-transformed to remove positive
skewness.
Baseline demographic, clinical, and radiographic cha-
racteristics of RA and UA patients were compared with
χ2 or Fisher Exact tests for discrete variables, and
unpaired t test or Kruskal-Wallis test for continuous
variables.
The association of adipokine levels and baseline radio-
graphic damage was tested by univariate and multiva-
riate linear regression analyses for patients with SHS >0.
Patients with SHS = 0 were removed from these analyses
after logarithmic transformation.
Univariate and multivariate logistic regression ana-
lyses were used to model radiographic progression as
a dichotomous variable, with the primary outcome
defined by any change in total SHS (∆SHS ≥1), as pre-
viously examined in the ESPOIR cohort [25,26]. Simi-
larly, erosive and narrowing disease progression was
defined as a ∆SHS ≥1 in erosive and narrowing sub-
scores, respectively. Additional analyses involved a stric-
ter outcome of any increase in total SHS ≥5 (∆SHS ≥5),
which delineates the subgroup of patients with rapid
radiographic disease progression, also previously exa-
mined in the ESPOIR cohort [27].
Relevant known confounders were included in multi-
variate analyses models. We consider four models as
follows: model 1, or “base” model, adjusted on age and
sex; Model 2, or “metabolic” model, adjusted on Model
1 variables and body mass index (BMI) and HOMA-IR
index; model 3, or “metabolic and RA” model, adjusted
on model 2 variables and CRP level, DAS28, HAQ
score, RF status, anti-CCP antibody status, and, for the
association with radiographic progression, presence of
typical damage related to RA at inclusion; and model 4,
or “metabolic, RA, and steroid” model, adjusted on
model 3 variables and steroid prescription at inclusion.
Sensitivity versus the false-positive frequency (1-spe-
cificity) for predicting radiographic disease progression
(∆SHS ≥1 or ≥5) with adipokines levels and with other
markers of radiographic disease progression (that is,
DAS28 value, number of swollen joints, CRP level, RF
level, and anti-CCP antibodies level) was analyzed with
a receiver-operated characteristic (ROC) curve. The
predictive accuracy of each item was assessed by using
the area under the curve (AUC). To determine the opti-
mal cut-off of adiponectin level, the Youden index was
calculated by using the following formula: sensitivity +
specificity – 1, and the maximum value of the Youden
index corresponded to the optimal cut-off point [28].
All statistical tests were two-sided with a statistical sig-
nificance defined as P < 0.05. SAS v9.3 (SAS Inst., Cary,
NC, USA) was used for analysis.
Results
Characteristics of the study population and comparison
of RA and UA patients
Among 813 patients enrolled in the whole cohort, 791
had data for serum adipokine levels and were analyzed
in this study; 632 had RA fulfilling the ACR-EULAR
2010 criteria, and 159 had UA. Comparisons of clinical,
biologic, and radiologic characteristics of RA and UA
patients are shown in Table 1. At inclusion, RA patients
were more often positive for anti-CCP antibodies and
RF and showed radiographic changes than did UA pa-
tients. In addition, DAS28, HAQ score, and CRP level
were significantly higher for RA than for UA patients.
Baseline total SHS was higher for RA than for UA pa-
tients, the difference involving predominantly the ero-
sive subscore. At 1-year follow-up, similar results were
observed, with a wider variation of total and erosive
SHS in the RA group.
Despite these differences, serum adipokine levels did
not significantly differ between RA and UA patients
(Table 1). However, adiponectin levels were higher for RA
patients with positivity for anti-CCP antibodies or RF than
for those without (5.22 ± 3.96 versus 4.58 ± 3.29 μg/ml;
P = 0.04). Leptin level was higher but not significantly for
patients without than for those with auto-antibodies
(13.75 ± 12.70 versus 15.47 ± 15.35 ng/ml; P = 0.07). Con-
versely, visfatin/NAMPT level did not vary by auto-
antibody status (P = 0.59).
Serum adipokine levels and structural damage for
patients with RA at baseline
Baseline serum adiponectin level was associated with
baseline total SHS even after adjustment for metabolic
and RA confounders, as well as steroid prescription
(model 4: β = 0.12; P = 0.006) (Table 2). This association
involved mainly the joint-narrowing subscore (model 4:
β = 0.14; P = 0.01). Conversely, leptin and visfatin/
NAMPT levels were not associated with total SHS on
univariate or multivariate analysis (Table 2).
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Association of adipokine levels and radiographic disease
progression
Serum level of each adipokine are graphically reported
in the Figure 1 according to the presence (n=160) or not
of radiographic progression at 1 year (that is, ∆SHS ≥1
or ∆SHS <1).
Baseline serum adiponectin level was associated with
radiographic disease progression (∆SHS ≥1) in both uni-
variate and multivariate models (Table 3, Figure 2). In
Model 3 (“metabolic and RA”), baseline serum adipo-
nectin level and radiographic progression at 1 year were
related (adjusted odds ratio (OR), 95% confidence inter-
val = 1.84 (1.24 to2.71), P = 0.002). In other words, with
each 1-unit increase in log(adiponectin) level, the risk of
radiographic progression at 1 year was increased 84%.
This association persisted after adjustment for steroid
prescription at inclusion (Model 4 in Table 3 and
Figure 2).
Similarly, baseline serum adiponectin level was asso-
ciated with erosive and narrowing disease progression
(defined as ∆SHS erosive subscore ≥1 and ∆SHS nar-
rowing subscore ≥1, respectively): adjusted (model 3)
OR = 1.73 (1.17 to 2.55) (P = 0.006) and 1.91 (1.04 to 3.52)
(P = 0.038), respectively (Table 3 and Additional file 1:
Figure S1). This association persisted even after adjust-
ment for steroid prescription at inclusion. No interaction
was seen between adiponectin level and the two other adi-
pokines levels, and the predictive value of adiponectin did
Table 1 Characteristics of patients with early rheumatoid arthritis (RA) and undifferentiated arthritis (UA) from the
ESPOIR cohort
UA (n = 159) Early RA (n = 632) P value
Age 47.2 ± 13.8 48.5 ± 12.2 0.46
Women (n,%) 117 (74%) 492 (78%) 0.25
First symptom (months) 6.6 ± 7.7 6.9 ± 8.5 0.72
DAS28 4.0 ± 1.0 5.4 ± 1.2 <0.0001
CRP level (mg/L) 17.2 ± 29.3 21.1 ± 33.1 0.0028
ESR 25.3 ± 22.4 30.6 ± 24.9 0.0014
Positive anti-CCP antibodies (n,%) 2 (1.26%) 313 (49.5%) <0.0001
Positive RF (n,%) 5 (3.1%) 365 (57.75%) <0.0001
Swollen-joint count 3.5 ± 2.4 8.2 ± 5.2 <0.0001
Tender-joint count 3.2 ± 2.6 9.9 ± 7.2 <0.0001
HAQ score 0.69 ± 0.58 1.05 ± 0.69 <0.0001
Diabetes mellitus (n,%) 7 (4.4%) 24 (3.8%) 0.73
HOMA-IR index 2.5 ± 2.6 2.8 ± 4.2 0.37
BMI 24.7 ± 4.6 25.2 ± 4.6 0.22
Steroid prescription at inclusion (n,%) 22 (13.8%) 84 (13.3%) 0.86
Radiographic damage at inclusion (n,%) 0 (0) 108 (17.1%) <0.0001
Total SHS at inclusion 4.6 ± 6.8 6.14 ± 7.92 0.005
Erosive SHS 1.6 ± 3.13 3.09 ± 4.98 <0.0001
Narrowing SHS 2.97 ± 4.82 3.04 ± 4.36 0.77
Total SHS at 1 year 5.7 ± 9.5 7.7 ± 10.7 0.006
Erosive SHS 2.35 ± 5.05 4.48 ± 7.56 <0.0001
Narrowing SHS 3.36 ± 5.54 3.26 ± 4.78 0.9552
Total ∆SHS between inclusion and 1 year 1.0 ± 3.8 1.6 ± 4.4 0.02
Erosive ∆SHS between inclusion and 1 year 0.73 ± 2.7 1.37 ± 3.73 0.0025
Narrowing ∆SHS between inclusion and 1 year 0.24 ± 1.22 0.26 ± 1.15 0.7294
Adiponectin level (μg/ml) 4.9 ± 3.4 5.0 ± 3.7 0.63
Leptin level (ng/ml) 14.6 ± 14.4 14.4 ± 13.7 0.74
Visfatin/NAMPT level (ng/ml) 4.1 ± 3.6 3.57 ± 3.1 0.47
Data are expressed as mean ± SD unless indicated. Bold P values are significant.
DAS28, Disease Activity Score in 28 joints; CRP, C-reactive protein level; ESR, erythrocyte sedimentation rate; anti-CCP, anti-cyclic citrullinated protein peptide
antibodies; RF, rheumatoid factor; HAQ, Health Assessment Questionnaire; VAS, visual analog scale; BMI, body mass index; HOMA-IR, Homeostatic Model
Assessment of Insulin Resistance, SHS, total Sharp/van der Heijde score; ∆SHS, variation in SHS between inclusion and 1 year.
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Table 2 Unadjusted and adjusted association of serum adipokine levels and total joint erosive and narrowing Sharp/van der Heijde score (SHS) at inclusion for
RA patients with SHS ≥1 (n = 446)
Univariate Model 1 “Base” Model 2 “metabolic” Model 3 “metabolic + RA” Model 4 “metabolic + RA + steroid”
β P β P β P β P β p
Adiponectin Total SHS 0.058 0.1 0.097 0.007 0.1 0.006 0.11 0.007 0.12 0.006
Erosive SHS −0.004 0.93 0.035 0.40 0.03 0.52 0.06 0.22 0.06 0.22
Narrowing SHS 0.097 0.03 0.1 0.02 0.13 0.006 0.14 0.009 0.14 0.01
Leptin Total SHS 0.015 0.75 0.015 0.73 −0.01 0.79 −0.01 0.76 −0.01 0.74
Erosive SHS −0.15 0.005 −0.13 0.01 −0.09 0.02 −0.06 0.14 −0.07 0.13
Narrowing SHS 0.13 0.02 0.11 0.047 0.04 0.40 0.02 0.64 0.03 0.63
Visfatin/NAMPT Total SHS 0.006 0.89 0.008 0.87 −0.01 0.82 −0.04 0.46 −0.04 0.46
Erosive SHS −0.08 0.11 −0.1 0.06 −0.12 0.03 −0.14 0.02 −0.14 0.02
Narrowing SHS −0.004 0.95 0.02 0.70 −0.009 0.89 −0.02 0.71 −0.02 0.71
Multivariate models: Model 1 (“base”): sex + age. Model 2 (“metabolic”): Model 1 + BMI + HOMA-IR index. Model 3 (“metabolic + RA”): Model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody
status. Model 4 (“metabolic + RA + steroid”): Model 3 + steroid prescription at inclusion. The following variables were log-transformed: CRP level, HAQ score, serum adipokine levels. Results are presented as β regression
coefficient and P value. Bold P values are significant.
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not change when serum leptin and visfatin/Nampt were
included in the model 4 (data not shown).
We strengthened our results with a more-stringent defi-
nition of radiographic disease progression (∆SHS ≥5;
n=54). Serum levels of each adipokine according to the
presence or absence of rapid radiographic progression are
graphically reported in Figure 1. We still found an associ-
ation of baseline serum adiponectin level and rapid radio-
graphic progression even after adjustment for all
considered confounders (model 4) (OR, 2.0 (1.14 to 3.52),
P = 0.02) (Table 4, Figure 2).
For leptin level, with radiographic disease progression
considered as ∆SHS ≥1 and after controlling on RA-related
and metabolic parameters, with each 1-unit increase in
log(leptin) level, the risk of radiographic progression at 1
year was increased 59% (model 3 or 4, OR = 1.59 (1.05 to
2.41); P = 0.03) (Table 3, Figure 2). This association was
exclusively to the result of erosive disease progression
(model 3 OR, 1.68 [1.1 to 2.56]; P = 0.01) (Table 3 and
Additional file 1: Figure S1). These results did not change
after controlling for steroid prescription (model 4). The
association of leptin level and radiographic progression
disappeared after adjustment when considering disease
progression as ∆SHS ≥5 (Table 4, Figure 3).
To estimate the accuracy of serum leptin and serum
adiponectin to independent prediction of radiographic
disease progression at 1 year (∆SHS ≥1 or ∆SHS ≥5), we
performed ROC curves analyses of these two adipokines
and also of other known markers associated with radio-
graphic disease progression or rapid radiographic disease
progression (/that is, DAS28 value, number of swollen
joints, CRP level, RF level, and ACPA level) (Figure 4 for
∆SHS ≥1 and Figure 5 for ∆SHS ≥5). Interestingly, the
AUC of each ROC curve of serum adiponectin and
ΔSHS<1 ΔSHS≥1 ΔSHS<5 ΔSHS≥5
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Figure 1 Dot blots and outlier boxplots of baseline serum adipokines levels according to the radiographic disease progression
(∆SHS ≥1 versus ∆SHS <1 and ∆SHS ≥5 versus ∆SHS <5) in early RA patients.
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Table 3 Association of baseline serum adipokine levels and radiographic disease progression defined as an increase of ≥1 in total SHS between inclusion and
1 year
Univariate model Model 1 “Base” Model 2 “Metabolic” Model 3 “Metabolic + RA” Model 4 “Metabolic + RA + steroid”
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Adiponectin Total ∆SHS ≥1 1.34 (1.03-1.76) 0.03 1.59 (1.19-2.12) 0.002 1.57 (1.16-2.13) 0.004 1.84 (1.24-2.71) 0.002 1.84 (1.25-2.72) 0.002
Erosive ∆SHS ≥1 1.34 (1.02-1.75) 0.03 1.56 (1.17-2.08) 0.003 1.54 (1.13-2.08) 0.006 1.73 (1.17-2.55) 0.006 1.73 (1.17-2.55) 0.006
Narrowing ∆SHS ≥1 1.65 (1.05-2.61) 0.03 1.79 (1.10-2.90) 0.02 1.95 (1.16-3.27) 0.01 1.91 (1.04-3.52) 0.04 1.93 (1.04-3.57) 0.04
Leptin Total ∆SHS ≥1 0.86 (0.71-1.05) 0.14 0.95 (0.76-1.18) 0.63 1.24 (0.9-1.70) 0.2 1.59 (1.05-2.41) 0.03 1.59 (1.05-2.42) 0.03
Erosive ∆SHS ≥1 0.88 (0.72-1.07) 0.19 0.96 (0.77-1.20) 0.69 1.29 (0.93-1.78) 0.12 1.68 (1.11-2.56) 0.01 1.69 (1.11-2.57) 0.01
Narrowing ∆SHS ≥1 0.93 (0.66-1.3) 0.66 0.93 (0.64-1.35) 0.70 1.09 (0.63-1.87) 0.76 1.1 (0.58-2.09) 0.76 1.10 (0.58-2.08) 0.77
Visfatin/NAMPT Total ∆SHS ≥1 1.22 (0.99-1.51) 0.06 1.20 (0.97-1.49) 0.09 1.2 (0.95-1.49) 0.12 1.09 (0.81-1.46) 0.57 1.09 (0.81-1.46) 0.58
Erosive ∆SHS ≥1 1.25 (1.01-1.54) 0.04 1.23 (0.99-1.52) 0.06 1.22- (0.98-1.53) 0.08 1.14 (0.85-1.53) 0.37 1.14 (0.85-1.54) 0.37
Narrowing ∆SHS ≥1 1.17 (0.82-1.67) 0.39 1.16 (0.81-1.67) 0.41 1.05 (0.73-1.53) 0.79 1.12 (0.72-1.75) 0.62 1.13 (0.72-1.77) 0.6
OR, odds ratio; 95% CI, 95% confidence interval. Total patient number, 530.
Data are unadjusted and adjusted odds ratios with p values. Bold P values are significant.
Radiographic progression is defined as variation in total SHS between inclusion and 1 year (total ∆SHS) ≥1.
Erosive radiographic progression is defined as variation in erosive SHS between inclusion and 1 year (erosive ∆SHS ≥1).
Narrowing radiographic progression is defined as variation in narrowing SHS between inclusion and 1 year (narrowing ∆SHS ≥1).
Multivariate models:
Model 1 (“base”): sex + age (n = 530).
Model 2 (“metabolic”): Model 1 + BMI + HOMA-IR index (n = 497).
Model 3 (“metabolic + RA”): Model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody status + presence of radiographic changes at inclusion (n = 344).
Model 4 (“metabolic + RA + steroid”): Model 3 + steroid prescription at inclusion (n = 344).
The following variables were log-transformed: CRP level, HAQ score, serum adipokine levels.
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serum leptin was in the same range as the AUC of base-
line DAS28, number of swollen joints, or CRP level
(P values nonsignificant). As expected and because of
the accuracy of autoantibodies, RF level and anti-CCP
antibodies level displayed higher AUC (P values <0.05).
Considering the higher values of sensitivity combined
with the lower values (1-specificity), the best cut-off for
serum adiponectin level was 4.14 μg/ml (sensitivity, 0.55,
and specificity, 0.58) and 6.04 μg/ml (sensitivity, 0.43, and
specificity, 0.75) to predict ∆SHS ≥1 or ≥5, respectively.
We also calculated the negative predictive value (75% and
92% for ∆SHS ≥1 or ∆SHS ≥5, respectively) and the
positive predictive value (36% and 16% for ∆SHS ≥1 or
∆SHS ≥5, respectively), suggesting that a nonelevation of
serum adiponectin beyond the threshold may imply that
the risk of radiographic disease progression is very low.
We used linear regression analyses to investigate the as-
sociation of baseline serum adipokine levels and total SHS
at 1 year to ensure the association of serum adiponectin
or leptin levels and radiographic disease progression. We
focused on patients with severe disease, with prevalent
radiographic lesions, because the log-transformed SHS
automatically excluded all patients with SHS of 0. Again,
serum adiponectin level predicted radiographic disease
damage at 1 year (model 4, β = 0.13, P = 0.0026; Additional
file 2: Table S1). Conversely, leptin level was not asso-
ciated with total SHS at 1 year.
Baseline visfatin/NAMPT levels did not predict radio-
graphic disease progression in any models, whatever the
definition of radiographic disease progression used.
Discussion
We used data for the French ESPOIR cohort, one of the
largest worldwide cohorts of early RA patients followed
up longitudinally. We demonstrated that, in patients ful-
filling the ACR-EULAR 2010 criteria for early RA at
Adiponectin Leptin Visfatin
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Figure 2 Association of baseline serum adipokine levels and radiographic evidence of disease progression defined as an increase of ≥1 in
total Sharp/van der Heijde score (SHS) between inclusion and 1 year. Multivariate models: model 1 (“base”): sex + age. Model 2 (“metabolic”):
model 1 + BMI + HOMA-IR index. Model 3 (“metabolic + RA”): model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody
status + presence of radiographic changes at inclusion. Model 4 (“metabolic + RA + steroid”): model 3 + steroid prescription at inclusion. DAS28,
Disease Activity Score in 28 joints; CRP, C-reactive protein level; ESR: erythrocyte sedimentation rate; RF, rheumatoid factor; HAQ, Health Assessment
Questionnaire; BMI, body mass index; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance.
Table 4 Association of baseline serum adipokine levels and rapid radiographic disease progression defined as an
increase of ≥ 5 units in total SHS between inclusion and 1 year (total ∆SHS ≥5)
Univariate model Model 1 “Base” Model 2
“metabolic”
Model 3
“metabolic + RA”
Model 4 “metabolic + RA
+ steroid”
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Adiponectin ∆SHS ≥ 5 1.47 (0.98-2.20) 0.06 1.7 (1.11-2.61) 0.02 1.85 (1.16-2.94) 0.01 2.0 (1.14-3.52) 0.02 2.0 (1.14-3.52) 0.02
Leptin ∆SHS ≥ 5 0.73 (0.54-0.97) 0.03 0.75 (0.55-1.04) 0.09 0.98 (0.61-1.56) 0.92 0.97 (0.55-1.68) 0.90 0.97 (0.56-1.68) 0.90
Visfatin/NAMPT ∆SHS ≥ 5 1.14 (0.83 1.56) 0.41 1.12 (0.82-1.54) 0.48 1.11 (0.79-1.55) 0.56 0.96 (0.64-1.44) 0.85 0.96 (0.64-1.44) 0.85
OR, odds ratio; 95% CI, 95% confidence interval.
Multivariate models:
Model 1 (“base”): sex + age.
Model 2 (“metabolic”): model 1 + BMI + HOMA-IR index.
Model 3 (“metabolic + RA”): model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody status + presence of radiographic changes
at inclusion.
Model 4 (“metabolic + RA + steroid”): model 3 + steroid prescription at inclusion.
The following variables were log-transformed: CRP level, HAQ score, serum adipokine levels. Bold P values are significant.
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Figure 3 Association of baseline serum adipokine levels and radiographic disease progression defined as an increase of ≥5 in total
SHS between inclusion and 1 year. Multivariate models: Model 1 (“base”): sex + age. Model 2 (“metabolic”): model 1 + BMI + HOMA-IR index.
Model 3 (“metabolic + RA”): model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody status + presence of radiographic
changes related to RA at inclusion. Model 4 (“metabolic + RA + steroid”): model 3 + steroid prescription at inclusion. DAS28, Disease Activity Score
in 28 joints; CRP, C-reactive protein level; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; HAQ, Health Assessment Questionnaire;
BMI, body mass index; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance.
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Figure 4 Receiver operating characteristic (ROC) curves for predicting radiographic progression (ΔSHS ≥1). The corresponding value of
area under the curve (AUC) is reported for each item.
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inclusion in the cohort, serum level of adiponectin is asso-
ciated with subsequent early radiographic disease progres-
sion, independent of several RA and metabolic
confounders and especially with rapid radiographic dis-
ease progression (∆SHS ≥5). Serum adiponectin level is
associated with both erosive and narrowing subscores of
radiographic disease progression.
Klein-Wieringa et al. [1,20] investigated adipokine
levels in 253 patients with early RA by using the 1987
ACR criteria, but we chose the new ACR-EULAR 2010
criteria, which do not involve radiographic results and
thus are more accurate for early RA diagnosis and more
adapted to identify new biomarkers of RA severity early
during the disease course.
Several cross-sectional studies of established RA have
shown a positive association of serum levels of adipo-
nectin and visfatin/NAMPT and an inverse association of
serum leptin level and radiographic joint damage [18,19].
However, we found that baseline serum adiponectin level
was associated with quantitative joint damage, as assessed
by SHS, mainly the joint-narrowing SHS subscore. Con-
versely, serum leptin was not associated with radiographic
RA damage after multiple adjustments. Several reasons
may explain such discrepancies. First, characteristics of
the population differed because we investigated a large
cohort of patients with early, not-established, untreated
RA, whereas Rho et al. [19] investigated 167 patients with
established RA of 3-year duration. Second, we analyzed
RA patients with SHS ≥1, characterized by a more severe
structural disease at inclusion, because of the logarithmic
transformation of SHS necessary to meet the assumption
of linear regression analysis. We found no association of
leptin level and radiographic progression by total SHS; this
finding is in agreement with that of Rho et al. [19], who
showed that the association of serum leptin level and
radiographic damage did not persist after adjustment for
BMI, considered an important confounder.
Several of our statistical analyses show that adiponectin
and leptin can predict radiographic progression and thus
disease severity. Although adiponectin could have protec-
tive roles in some tissues [8], preclinical studies have
demonstrated its deleterious role in cartilage homeostasis.
Adiponectin induces the release of proinflammatory cyto-
kines (that is, IL-6, monocyte chemotactic protein-1
(MCP-1)), pro-degradative enzymes (that is, matrix metal-
loproteinases (MMPs)) and nitric oxide in chondrocytes
[29-33]. These experimental data may explain, at least in
part, a link between serum adiponectin level and joint-
space narrowing found in our study. Moreover, synovial
fibroblasts express adiponectin receptors and are reac-
tive to adiponectin stimulation, triggering a proin-
flammatory and prodegradative state characterized by
Adiponectin
AUC=0.57
DAS28
AUC=0.50
Swollen joints
AUC=0.53
CRP
AUC=0.53
RF level
AUC=0.67
Anti-CCP level
AUC=0.69
Leptin
AUC=0.59
Visfatin
AUC=0.52
Figure 5 Receiver operating characteristic (ROC) curves for predicting radiographic progression (ΔSHS ≥5). The corresponding value of
area under the curve (AUC) is reported for each item.
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prostaglandin E2, IL-6, IL-8, MCP-1, and MMPs re-
leases [29,33,34].
Furthermore, the paradoxic adiponectin effects bet-
ween the cardiovascular system and joints may be re-
lated to its different isoforms. However, all adiponectin
isoforms were shown to exert a proinflammatory and
joint-destructive role on synovial cells [35]. Moreover,
we previously compared levels of total and of the main
isoform of adiponectin, “high-molecular-weight” (HMW)
adiponectin in a large number of individuals with a wide
range of BMI (n = 408). We found that total adiponectin
and HMW-adiponectin were highly correlated (r = 0.927;
P < 0.001, JP Bastard, personal communication). There-
fore, total serum adiponectin level could be considered a
good reflection of the HMW-adiponectin level. However,
the direct assessment in the serum of the several adi-
ponectin isoforms remains to be investigated in RA to
compare its accuracy with serum total adiponectin level
to predict structural progression.
Giles et al. [21] performed a cross-sectional study
assessing the association of serum adipokine levels and
radiographic damage and showed an association of high
adiponectin level and erosions, as well as joint narrow-
ing. Our study is the first to investigate the longitudinal
association of serum adipokine levels and SHS subscores
(that is, erosive and narrowing SHS). Here, we found
that adiponectin level may predict joint erosive as well
as narrowing disease progression at 1 year, which illus-
trates the long-term effect of this adipokine on all cell
types within the RA joint [29-36].
We also found that the leptin level is a reliable surro-
gate biomarker of disease progression. The predictive
value of leptin seems weaker than that of adiponectin,
because we found no association of baseline leptin level
and structural damage at inclusion of RA patients or
subsequent rapid disease progression (∆SHS ≥5). In-
terestingly, two longitudinal studies obtained similar
results: no predictive value of serum leptin level for
radiographic disease progression [20,21].
Considering the direct link between serum adipokine
levels and metabolic disorders such as obesity, type 2 dia-
betes, insulin resistance, or metabolic syndrome [37-39],
our interpretation of serum adipokine levels by multivari-
ate analysis included not only BMI, but also an estimate of
insulin resistance by the HOMA-IR index was not consi-
dered in previous studies [18-21]. Likewise, we included
the HOMA-IR index among the “metabolic confounders”
in multivariate models. Interestingly, the association of
adiponectin or leptin level and radiographic disease pro-
gression persisted in these models. Adiponectin level may
be independent of fat-tissue status in exerting a delete-
rious effect on RA joints, and thus is not the sole biologic
explanation for the protective effect of obesity on RA joint
damage [40,41].
Treatment at baseline, especially corticosteroids, may
modify adipokine levels [42,43]. In the ESPOIR cohort,
most patients were untreated at the time of inclusion, but
about 14% received steroids for a short time before inclu-
sion. We included steroid prescription as a confounder in
our multivariate analysis (model 4). Steroid use modulates
adipokine levels themselves [42,43]. Interestingly, steroid
prescription did not modify the association of serum adi-
pokine levels and radiographic changes, so use of steroids,
given to patients with more severe disease, cannot explain
the link between adipokine levels and RA progression.
We found no association of visfatin/NAMPT levels
and RA, which disagrees with the cross-sectional study
of Rho et al. [19] but agrees with data from a recent lon-
gitudinal study [20]. Thus, the use of this adipokine as
serum biomarker seems more elusive than adiponectin.
One limitation of our study is that some concerns may
be raised by the definition of radiographic progression as
SHS ≥1. However, to ensure the strength of our results,
we performed two sensitivity analyses. First, we chose
another more-stringent definition of radiographic progres-
sion (∆SHS ≥5), which corresponds to the destruction of
one small rheumatoid joint, thereby delineating rapid
radiographic progression [27]. With this definition, never
used in previous studies on serum adipokines [20,21], the
associations persisted, which suggests that adiponectin
may accurately differentiate slow and fast disease progres-
sion. Second, we performed a linear regression analysis
searching for a correlation between baseline adipokine
levels as continuous variables and SHS values at 1 year.
Baseline adiponectin again was associated with structural
damage at 1 year.
Since we identified serum adiponectin level as a predict-
ive marker of subsequent structural disease progression,
we have attempted to determine the best threshold by
using ROC curves analyses (4.14 μg/ml for ∆SHS ≥1 and
6.04 μg/ml for ∆SHS ≥5). These two cut-offs display good
specificity (58% and 75% for ∆SHS ≥1 and ∆SHS ≥5, res-
pectively) and high negative predictive value (75% and
92% for ∆SHS ≥1 or ∆SHS ≥5, respectively), especially for
rapid radiographic progression. Thus, a serum adiponectin
below these two thresholds may exclude the risk of struc-
tural progression.
The next step for the validation of serum adiponectin is
to model a matrix that would combine serum total adipo-
nectin with other markers (anti-CCP antibodies status,
CRP level, baseline swollen-joint count, and erosions seen
on radiography) [27]. Furthermore, even if serum adipo-
nectin measurement has drawbacks, such as low sensiti-
vity and positive predictive value, its predictive accuracy
is in the same range as other recognized predictive
markers of radiographic progression, according AUC
(that is, DAS28 value, number of swollen joints, and
CRP level). Finally, the independent association between
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serum adiponectin level and RA progression replicated
here in such a large cohort gives pathophysiologic clues
about the involvement of adipokines in the early clinical
phase of RA and clearly demonstrates the link between
a high level of serum adiponectin and structural disease
progression.
Conclusions
We demonstrated that serum adiponectin level at the
time of RA diagnosis represents a surrogate biomarker
of early radiographic disease progression in patients ful-
filling the new ACR-EULAR 2010 criteria and thus may
accurately identify patients at high risk of early joint
destruction independent of inflammation, autoantibody
status, and metabolic disturbances.
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